FILANA THERAPEUTICS INC. - COMMON STOCK

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

22 Sep 2026 08:00:01 بحسب Nasdaq GlobeNewswire

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

13 Jan 2026 08:00:00 بحسب Nasdaq GlobeNewswire

Cassava Announces Agreement to Settle Securities Class Action Litigation

23 Dec 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Cassava Reports Q3 2025 Financials Results and Provides Business Update

12 Nov 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

22 Oct 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

25 Aug 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Cassava Reports Q2 2025 Financials Results and Provides Business Update

14 Aug 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

07 Aug 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

04 Aug 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

30 Jun 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Cassava Reports Q1 2025 Financials Results, Provides Business Update

08 May 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

01 May 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

21 Apr 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

25 Mar 2025 08:05:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

03 Mar 2025 07:30:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences Licenses Simufilam Method of Treatment Patent

27 Feb 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences Provides a Business Update

07 Jan 2025 16:30:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints

25 Nov 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Cassava Sciences to Hold Corporate Update on November 25th

24 Nov 2024 20:01:09 بحسب Nasdaq GlobeNewswire

Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer

18 Nov 2024 08:30:00 بحسب Nasdaq GlobeNewswire